Interim results for phase 1b dose expansion of Mtl-Cebpa in combination with pembrolizumab in patients with advanced solid tumour malignancies
dc.contributor.author | Plummer, R. | |
dc.contributor.author | Sodergren, M. | |
dc.contributor.author | Ryan, B. | |
dc.contributor.author | Tachkov, I. | |
dc.contributor.author | Reebye, V. | |
dc.contributor.author | Meyer, T. | |
dc.contributor.author | Pinato, D. | |
dc.contributor.author | Sarker, D. | |
dc.contributor.author | Basu, B. | |
dc.contributor.author | Blagden, S. | |
dc.contributor.author | Cook, Natalie | |
dc.contributor.author | Evans, J. | |
dc.contributor.author | Yachnin, J. | |
dc.contributor.author | Chee, C. E. | |
dc.contributor.author | Li, D. N. | |
dc.contributor.author | El-Khoueiry, A. | |
dc.contributor.author | Diab, M. | |
dc.contributor.author | Huang, K. W. | |
dc.contributor.author | D'Alessio, A. | |
dc.contributor.author | Fulgenzi, C. | |
dc.contributor.author | Noel, M. | |
dc.contributor.author | Keenan, B. | |
dc.contributor.author | Mahalingam, D. | |
dc.contributor.author | Raulf, N. | |
dc.contributor.author | Hogson, R. | |
dc.contributor.author | Tan, C. P. | |
dc.contributor.author | Nicholls, J. | |
dc.contributor.author | Adderkin, A. | |
dc.contributor.author | Vassiliadou, J. | |
dc.contributor.author | Habib, R. | |
dc.contributor.author | Rossi, J. | |
dc.contributor.author | Habib, N. | |
dc.date.accessioned | 2023-05-17T09:50:55Z | |
dc.date.available | 2023-05-17T09:50:55Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Plummer R, Sodergren M, Ryan B, Tachkov I, Reebye V, Meyer T, et al. Interim Results for Phase 1b Dose Expansion of Mtl-Cebpa in Combination with Pembrolizumab in Patients with Advanced Solid Tumour Malignancies. Journal for immunotherapy of cancer. 2022 Nov;10:A888-A9. PubMed PMID: WOS:000919423400804. | en |
dc.identifier.doi | 10.1136/jitc-2022-SITC2022.0850 | en |
dc.identifier.uri | http://hdl.handle.net/10541/626281 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1136/jitc-2022-SITC2022.0850 | en |
dc.title | Interim results for phase 1b dose expansion of Mtl-Cebpa in combination with pembrolizumab in patients with advanced solid tumour malignancies | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Newcastle University, Newcastle-upon-Tyne, | en |
dc.identifier.journal | Journal for Immunotherapy of Cancer | en |
dc.description.note | en] |